
perrigo compani plc focus develop
distribut private-label gener brand
over-the-counter prescript drug private-label nutrit
product activ pharmaceut ingredi
follow releas updat revenu ep estim
last week report disappoint result lower guidanc
previou expect howev encourag decis separate/
sell rx segment follow challeng quarter deterior market dynam
believ move like creat investor/analyst churn near term
open capit alloc capac focu grow chca
chci segment longer term although sale like take coupl quarter
complet believ shift attract consumer-focus investor base
lead upsid weak share perform follow report
remain buy rate share
overal result came expect consolid revenu
modestli miss expect came bn expect
bn consensu bn chca revenu mm estim
mm consensu mm chci revenu mm
expect mm consensu mm prescript pharmaceut
revenu mm expect mm consensu
expect mm adjust ep expect vs
estim consensu
guidanc lower reflect challeng rx outlook revis expect
reflect challeng gener environ full year revenu
expect rang bn bn previous expect
bn bn adjust ep expect previou
expect incorpor delay gener proair chca
revenu expect unchang oper margin expect
rang previous chci revenu expect bn
bn due impact unfavor fx shift rx revenu expect
mm significantli previous expect bn driven product
launch delay wors expect price eros poor perform
rx account ep reduct product delay includ gener
proair scopolamin account
shift focu toward consum side could caus nt volatil lt
growth come heel challeng quarter gener pleas
decis sell rx segment albeit like nt valuat challeng
investor/analyst churn stori shift pure play consum model believ
sale could provid capit capac shift focu away deterior
market grow chca chci vertic despit delay product launch
higher expect price eros gener portfolio could
provid signific increment cash flow buyer believ
segment may fetch average-to-above-averag multipl marketplac addit
pleas licens agreement merck
assum respons regulatori approv distribut non-prescript
nasonex although one product indic trend believ could
continu look rx-to-otc valuabl product area signific
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
consolid revenu modestli miss expect came
bn expect bn consensu bn chca revenu
mm estim mm consensu mm chci
revenu mm expect mm consensu mm
prescript pharmaceut revenu mm expect
mm consensu expect mm adjust ep
expect vs estim consensu
figur perrigo financi perform cgie consensu
chang estim
follow public compani updat revenu
ep estim
figur chang revenu ep estim
buy unchang target price august
price target deriv dcf consid wacc
risk rate price target
long-term chca growth depend rx-to-otc shift new categori
usual drive low-single-digit growth consum health america
chca busi though increas privat label uptak off-set somewhat retail
price pressur believ signific sustain growth chca busi
driven addit categori switch prescript over-the-counter condit
littl control brand pharma compani fda
resist move statin topic pain nsaid overact bladder treatment
erectil dysfunct product migrain product asthma inhal ophthalm
allergi dry-ey treatment over-the-counter could see pressur chca segment
despit domin share chca addit competitor start gain
long held domin share private-label over-the-counter market recent
over-the-counter switch seen steadi competit tradit prescript gener
compani seek gain traction over-the-counter retail typic assumpt
share given pl over-the-counter market longer guarante
believ continu increment competit could significantli slow perrigo
consum health intern chci busi may prove drag
take correct action segment follow challeng
belgian busi believ growth could slow segment follow brexit
potenti fx challeng continu restructur busi
buy unchang target price august
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price august
million usd except per share non-gaaprevenueconsum healthcar healthcar profit oper expensescost ipr oper expensestysabri chang expens expense/ incom sale invest -- -- -- -- -- -- -- -loss extinguish non-oper net incomeincom tax analysisbas per share share figur perrigo dcf model
buy unchang target price august
million usd except per share healthcar healthcar depreci amort exclud chang growth estim period long-term period net debt share outstand compani
